Core Insights - Alector, Inc. is a clinical-stage biotechnology company focused on therapies for neurodegenerative diseases, particularly Alzheimer's and Parkinson's, utilizing its Alector Brain Carrier platform [1] Financial Performance - Alector reported a quarterly loss of $0.34 per share, which was better than the expected loss of $0.39, resulting in a 13.71% earnings surprise [3][6] - The company's revenue for the quarter ending December 2025 was $6.24 million, exceeding expectations by 103.43%, but down significantly from $54.24 million reported a year ago [4][6] - Alector has consistently surpassed consensus revenue estimates in three of the last four quarters [4] Financial Position - Alector's financial position includes $256 million in cash, cash equivalents, and investments, which is expected to support operations through 2027 [5] - The company's current ratio is 3.83, indicating a strong ability to cover short-term liabilities [5][6] - However, the enterprise value to operating cash flow ratio is -1.36, suggesting challenges in generating positive cash flow from operations [5]

Core Insights - Alector is advancing its Alector Brain Carrier (ABC) platform across various therapeutic modalities, including antibodies, enzymes, and siRNA, with significant progress in treatments for Alzheimer's and Parkinson's diseases [1][4][16] - The company reported a cash position of $256.0 million as of December 31, 2025, which is expected to fund operations at least through 2027 [2][18] - Alector's CEO emphasized the unique capabilities of the ABC platform and its potential to translate scientific innovation into clinical assets [3] Financial Performance - Collaboration revenue for Q4 2025 was $6.2 million, a decrease from $54.2 million in Q4 2024, with total annual collaboration revenue dropping to $21.0 million from $100.6 million [13] - Research and development expenses for Q4 2025 were $32.5 million, down from $46.5 million in Q4 2024, with total R&D expenses for the year at $123.1 million compared to $185.9 million in 2024 [14] - General and administrative expenses for Q4 2025 were $13.3 million, a slight decrease from $15.0 million in Q4 2024, with annual G&A expenses at $54.0 million compared to $59.6 million in 2024 [15] Pipeline and Program Updates - Alector is advancing AL137, an ABC-enabled anti-amyloid antibody for Alzheimer's, with an IND application expected in Q4 2026 or Q1 2027 [8] - AL050, an ABC-enabled GCase enzyme replacement therapy for Parkinson's disease, is in preclinical development with an IND application targeted for 2027 [9] - The company is also progressing its ABC-enabled siRNA platform, with AL064 selected as the lead candidate for tau-related therapies [16] Clinical Trials - The PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer's disease is ongoing, with an independent interim futility analysis expected in the first half of 2026 [1][16]

Progranulin (PGRN)-Elevating Franchise - Alector's pivotal Phase 3 data readout for Latozinemab (AL001) in FTD-GRN is expected by mid-Q4 2025[13, 65] - The Phase 2 clinical trial for Nivisnebart (AL101/GSK4527226) in Alzheimer's Disease completed enrollment in April 2025[13, 68] - Latozinemab and nivisnebart have demonstrated a 2- to 3-fold increase in PGRN levels in clinical trials[50] - In the INFRONT-2 trial, Latozinemab treatment showed an estimated ~48% slowing of annual disease progression in FTD-GRN participants compared to historical controls, representing a 31-point change[61] Alector Brain Carrier (ABC) Platform - Alector expects to initiate a first-in-human clinical trial with its Alector Brain Carrier in 2026[13, 120] - AL037, an ABC-enabled anti-Aβ antibody, at 3mg/kg reached 38 nM in vessel-containing frontal cortex in NHP, showing an 18x increase compared to the naked antibody[114] - AL137, a second anti-Aβ antibody lead, at 3mg/kg reached 84 nM in vessel-containing frontal cortex in NHP, showing a 32x increase compared to the naked antibody[117] - AL050, an ABC-enabled GCase ERT, demonstrated a 5- to 19-fold enhancement in brain delivery in NHPs[149] - Peripheral delivery of SOD1 siRNA-ABC resulted in 50-80% knockdown across multiple brain structures in mice[171] Financial Resources - Alector has over $300 million in cash, providing a runway into the second half of 2027[13]